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Serum digoxin assay is a useful clinical tool in monitoring
the administration of digoxin. Its value, however, is gen-
erally overrated; judicious use of it applies only to spe-
cific clinical problems. Its primary use involves assay
values at the two ends of the scale: low ranges may help
Clinical pharmacology became a new discipline some three
decades ago, transferring the study of drug actions from the
experimental animal to the patient. The development of
methods for determining the concentration of drugs in the
tissues and body fluids permitted study of pharmacody-
namics and drug metabolism . The availability of drug assays
in the blood or serum permitted their adaptation for moni-
toring drug usage in patients.
Serum drug assays have been widely used for a variety
of therapeutic agents : however, their judicious clinical use
requires specific therapeutic objectives . As a rule, serum
assays are not needed for drugs with obvious and clinically
measurable effects (for example, diuretic drugs and anti-
hypertensive drugs). A reasonable indication for their use is
the detection of drug toxicity, particularly if the therapeutic
zone (the range between the minimal effective dose and the
toxic dose) is narrow. Drug assays may also be needed when
drugs are used solely for prophylactic purposes. Finally,
drug assays may play an important role in the evaluation
of drug action for agents with variable absorption and
metabolism .
Pharmacodynamics of Digoxin
Among the unusual features of digitalis is its dual phar-
macologic action. Its dromotropic effect is used clinically
to slow ventricular rate in patients with atrial fibrillation and
atrial flutter; its inotropic action is used to strengthen ven-
tricular contractility in patients with cardiac failure. The use
of digitalis in atrial fibrillation has an easily detectable ef-
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detect noncompliant patients or those with serious ab-
sorption difficulties. Higher ranges are helpful in the
clinical recognition of digitalis toxicity.
(J Am CoU CardioI1985;5:106A-llOA)
feet, which permits setting a therapeutic objective and mon-
itoring its action. Its effect in cardiac failure is almost im-
possible to detect clinically, particularly since this drug is
almost always part of a combined therapeutic intervention.
Digitalis shows wide variability in the dose-effect relation;
hence, effective doses vary widely. Digitalis effect is also
related to a variety of intrinsic and extrinsic factors that can
enhance or suppress its action . Considering these features ,
digitalis, with its narrow therapeutic zone, appears to be
suitable for monitoring by means of serum assay, particu-
larly when this drug is used for its inotropic effect in cardiac
failure .
Distribution of digoxin in tissues and body fluids. This
was studied extensively when radioactive digoxin became
available (1-3); such studies replaced the rather cumbersome
biologic methods (4). Evaluation of the pharmacodynamics
of digoxin showed two stages of its distribution (5). The
first (half-life of about 50 minutes) consists of rapid dis-
appearance of digoxin from serum, thought to be due to
tissue distribution of this drug . Thereafter, there is a " steady
state" with a slow decrease in digoxin serum concentration
that reaches a plateau at 4 to 6 hours and has a half-life of
about 30 hours. Digoxin is distributed to most tissues. Its
highest tissue concentration is present in the kidneys since
this is where this drug is excreted; the heart has the second
highest concentration . A reasonable correlation between the
concentration of digoxin in the heart and in the serum was
demonstrated; hence, serum digoxin concentration does re-
flect the concentration of this drug in the heart muscle.
Serum digoxin concentration. The serum concentra-
tion of digoxin increases rapidly , regardless of the mode of
administration (5), to levels three to five times the steady
state concentration and then falls rapidly, initiating the sec-
ond stage of distribution. Steady state, as noted (in reality
a very slowly falling level), is usually attained in 4 to 6
hours.
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The use of tritiated digoxin provided the in[ormation
regarding the pharmacodynamics of this drug. The clini-
cally applicable method of determining serum digoxin con-
centration was first based on the observation that digitalis
inhibits potassium in the heart muscle as well as in rhe red
'!
blood cells. This principle was used to measure the inhi-
bition of rubidium-86 (a potassium analog) in red mood
cells, showing that this method has a good correlatiorl with
serum digoxin concentration (6,7). However, it wds the
development of the radioimmunoassay technique, which
provided an easily available clinical method for digoxin
assay, that led to wide availability of this technique in clin-
ical laboratories (8).
At present, the method used for radioimmunoassay of
digoxin rt?quires certain precautions. The time fof sampling
has to be within the steady state of digoxin distribution,
optimally 4 to 6 hours after the last dose of digoxin. The
test should be performed by experienced technicians who
are aware of the need for accuracy of standartls and use of
good counting equipment (9). It is important to recognize
that the administration of diagnostic tests using radionuclide
techniques may introduce error into calculations. The serum
concentration of digoxin ranges from 0.5 to 4 or more ng/ml,
and the therapeutic range is generally considered to be be-
tween 0.8 and 2 ng/m!. The zone between .2 and 3 ng/ml
is considered borderline; that above 3 rig/rnl is "toxic" (7).
Digoxin Dosage
The dosage of digoxin ranges from O. 125 to 0.5 mg/
24 h. It is a drug with a long half-life, primarily used for
its long-term effect (intravenous digoxin is used almost ex-
clusively for its effect in atrial fibrillation). The full effect
of digoxin can be obtained after 5 to 7 days of daily admin-
istration (slow digitalization) (10). To attain the full ther-
apeutic effect earlier, a loading dose of I to 1.5 mg has to
be administered within 12 to 24 hours. These doses of dig-
oxin represent average maintenance doses. Wide variability
of effect makes it necessary to administer doses as small as
0.0625 rug/day or as large as I mg/day to obtain therapeutic
responses in some cases.
Digoxin dosage in atrial fibrillation versus sinus
rhythm. Digoxin doses can be calculated adequately only
in patients in atrial fibrillation, using ventricular rate as a
target point. As will bediscussed, serum digoxin assays are
not suitable as guidelines for digitalis dosage. Some years
ago, attempts were made (II) to calculate individual digoxin
dosage in patients who were taking this drug for its inotropic
effect (where clinical monitoring of effects is not available).
As a basis for calculation, renal function and body weight
were utilized to construct dosage nomograms (II). How-
ever, renal function is only one of many factors responsible
for drug dose variability; hence, the ptactical value of such
nomograms was not considered sufficient for their adoption.
The dosage of digoxin used in the treatment of cardiac
failure in patients in sinus rhythm presents difficulties in
selecting maintenance therapy. This is because the varia-
bility of the dose-effect ratio is unusually wide for this drug
and clinical guidelines are riot available. The lack of know1-
edge of whether an individual patient in sinus rhythm has
obtained full benefit of the .action of digoxin is one cause
of the current controversy regarding the value of digoxin
maintenance in the treatment of chronic cardiac failure (12).
Role of Digoxin Assay in Digitalis Toxicity
Digitalis toxicity occurs commonly and is often life-
threatening. Its diagnosis and its avoidance on the basis of
monitoring digoxin assay was the first objective of this tech-
nique when it was initially developed (13). Clinical diag-
nosis of digitalis toxicity is often difficult because in patients
seriously ill with heart disease most of its manifestations
could be caused by the disease, not by the drug. Digitalis
toxicity is a major clinical problem in patients with cardiac
disease: the 1971 study by Beller et al. (14) showed that
23% of patients taking digitalis on hospital admission showed
definite evidence bf drug toxicity; another 6% had possible
drug toxicity. Mortality in patients showing drug toxicity
was twice that in those without evidence of toxicity. Opin-
ions have been expressed (IS) that digitalis toxicity is less
prevalent now as a result of the wide use of digitalis assay.
The use ofdigoxin assay in the diagnosis ofdrug toxicity
is based on the observation that in patients with clinical
manifestations of digitalis toxicity generally the serum dig-
oxin assay is in excess of 2 ng/ml. A recent review (9) lists
40 studies comparing patients with and without digoxin
toxicity in regard to serum assay. The mean serum digoxin
concentration in patients without drug toxicity was less than
2 ng/ml in all but two studies; in patients showing clinical
evidence of toxicity, the mean serum concentration was
above 2 ng/ml in all but four studies. However, this merely
gives a valid statistical and epidemiologic dividing line be-
tween therapeutic and toxic ranges of digoxin. The wide
overlap of individual readings does not permit us to consider
serum levels above 2 ng/ml as indicative of digitalis toxicity.
This question was evaluated by Ingelfinger and Goldman
(16), who criticized the concept of toxic digoxin levels
above 2 ng/ml on the basis that most studies did not use
controls. They pointed out that it is difficult to design studies
to determine whether digitalis concentration helps in the
diagnosis of digitalis toxicity in the light of the absence of
an independent proof that toxicity is present. These inves-
tigators concluded that the superiority of the assay over the
use of clinical criteria in demonstrating digitalis toxicity is
not proven.
Perhaps the most important point concerning digitalis
toxicity is the presence of factors that alter the sensitivity
to digitalis. These fall into two categories: I) those affecting
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Table 1. Factors Facilitating Development of Digitalis Toxicity 6.0 CHRONIC ATRIAL FIBRILLATION - STABLE
With increase in serum digoxin concentration
Renal failure
Drug interactions
Without affecting serum digoxin concentration
Myocardial disease
Ischemic states
Cardiomyopathy
Electrolyte imbalance
Hypoxemia
Hypothyroidism
Electroshock
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Figure 2. Relation between heart rate and serum digoxin levels
in 38 patients in Group 18 (chronic atrial fibrillation with com-
plicating serious illness). (Reproduced from Goldman S, et al. [17)
with permission.)
Figure 1. Relation between heart rate and serum digoxin levels
in 15 patients in Group lA (chronic atrial fibrillation, clinically
stable condition). Closed circles falling within the box represent
patients with "therapeutic" serum digoxin concentrations (0.8 to
2.0 ng/ml) in combination with "controlled" ventricular rates (65
to 95 beats/min). (Reproduced from Goldman S, et al. [17) with
permission.)
inadequately controlled at therapeutic levels. In Group lB,
5 patients required doses bringing their serum digitalis con-
centration to between 2 and 5 ng/ml, 12 had inadequate
control of ventricular rate at therapeutic digoxin levels and
4 had inadequate control even at "toxic" levels. In the group
with acute atrial fibrillation (Group 2), the ventricular rate
of 18 patients was inadequately controlled at therapeutic
digoxin levels, required "toxic" doses for control in 9 pa-
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the pharmacodynamics of the drug, thereby requiring larger
or smaller doses to attain serum concentrations within the
therapeutic range; and 2) those affecting the sensitivity to
digitalis that may cause cardiotoxicity at levels considered
nontoxic (Table 1).
Use of Digitalis in Atrial Fibrillation
As stated, the action of digitalis in slowing ventricular
rate in atrial fibrillation provides a predictable effect that
can be clinically monitored. Untreated atrial fibrillation in
patients with a normally functioning atrioventricular (AV)
node is associated with a ventricular rate ranging from 140
to 180 beats/min. Depending on clinical urgency, digoxin
can be used intravenously or orally; as a rule, rapid digi-
talization is used, so that either mode of administration
requires a loading dose. The intravenous route produces
initial slowing within 30 minutes to 1 hour. The first effects
of an oral dose are usually apparent several hours after the
loading dose. The therapeutic goal of digitalis administra-
tion is to slow the ventricular rate to a rest level of 60 to
80 beats/min, with a slight increase during mild exercise.
Digoxin dosage versus serum assay. Studies performed
in our laboratory (17) evaluated the relation between digi-
talis administration, serum digoxin assay and digoxin dos-
ages. Patients were placed into three groups: Group IA
included those with atrial fibrillation and stable clinical state
on a maintenance dosage of 0.25 to 0.375 mg/day (Fig. 1);
Group IB consisted of patients in chronic atrial fibrillation,
with an unstable clinical state due to complicating problems,
who received incremental digitalis supplemental doses of
0.5 to 2.25 mg over 24 to 48 hours (Fig. 2); Group 2
included patients with acute (recent onset) atrial fibrillation
with doses of digoxin up to 2.5 g (Fig. 3). Adequately
controlled ventricular rates (65 to 95 beats/min) and ther-
apeutic serum assay (0.8 to 2.0 ng/ml) were obtained in 5
(31%) of 16 patients in Group lA, 7 (25%) of 28 patients
in Group lB and 5 (16%) of 30 patients in Group 2. In
Group lA, the ventricular rate of four patients was con-
trolled at subtherapeutic digoxin levels and that of five was
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Figure 3. Relation between heart rate and serum digoxin levels
in 32 patients in Group 2 (acute atrial fibrillation) . (Reproduced
from Goldman S, et al. [17] with pennission.)
tients and could not be controlled despite " toxic" digoxin
levels in 4 patients .
Results of this study show the wide variability of re-
sponses to digitalis administration . taking into considera-
tion the dosages and serum digoxin levels. Buildup of dig-
oxin levels to what is generally considered toxic range is
frequently necessary to adequately control ventricular rate.
Clinical criteria for possible toxicity, rather than serum as-
say , are used to set the limit of digitalis in patients whose
ventricular rate cannot be controlled by digitalis alone .
Digitalis in Sinus Rhythm
Whereas in patients with atrial fibrillation digoxin doses
can be individually adjusted using ventricular rate as a
guideline, no such drug monitoring opportunity exists when
digoxin is used for cardiac failure in patients in sinus rhythm.
Digoxin dose has to be used by arbitrary schedules that were
derived from extrapolation of results of digitalis effect in
atrial fibrillation. This is based on the assumption that the
dose-effect relation of digoxin used for its dromotropic ac-
tion is identical to that used for its inotropic action . This
assumption appears reasonable with some qualifications.
Ventricular rate in atrial fibrillation (an index of digitalis
effect) is also related to the sympathetic nervous system
" drive," which probably does not exert any effect on dig-
italis inotropy. It is important to consider that in atrial fi-
brillation, average digitalis dosages and " therapeutic" serum
levels fulfill the expected effect in less than 50% of patients
(17) . No evidence has yet been presented to show that the
level of serum digitalis concentration can be used as a guide
to therapy (that is, that digitalis at a serum level of 1.8 ng/ml
is more effective than that at a level of 0 .6 mg/min). Quan-
tification of the inotropic effect of digitalis is very difficult,
if not impossible. Extrapolation of the wide range of re-
sponses in atrial fibrillation over the entire scale of assay
(from inadequate to toxic ranges) suggests that digoxin assay
level is not a suitable guide when administering digoxin for
cardiac failure .
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Clinical Significance of Serum Assay
From the foregoing discu ssion , the following tentative
conclusions can be drawn regarding the role of serum dig-
oxin assay as an aid in treatment. Subtherapeutic levels of
digoxin « 0 .5 ng/ml) indicate a high probability that the
patient either does not take the drug regularly or has some
problem with absorption. Thus, it can be used as a check
of patient compliance, particularly when a patient is known
to have had adequate levels in the past.
Digoxin at therapeutic levels (0.5 to 2 ng/ml) adds little
as a guide to therapy. The inability to judge the adequacy
of digitali s effects from serum assay has been mentioned.
Furthermore, a digoxin level at the upper half of the ther-
apeutic range does not exclude the possibility of toxicity in
patient s with increased sensitivity to digoxin . It is also im-
portant to know the potassium serum level , this being the
most common potentiating factor producing digitalis toxicity.
Digoxin levels above 2 nglml do not prove digitalis tox-
icity . The y merely indicate that toxicity is possible . The
best use of high serum digitalis level s is in the interpretation
of arrhythmias occurring in patients (in both sinus rhythm
and atrial fibrillation ). Arrhythmias usually associated with
digitali s toxicity can be reasonably assumed to be caused
by this drug when the serum digoxin concentration exceeds
2 ng/m!. Similar arrhythmias found in patients with low
serum digoxin levels can be assumed to be related to the
underlying disease. As indicated , control of ventricular rate
in atrial fibrillation may require attainment of "toxic" serum
levels of digoxin. Cautious use of higher digoxin doses is
not contraindicated in such cases, provided that all possible
signs for digitalis toxicity are being looked for. However,
currently available alternate drugs capable of slowing ven-
tricular rate in atrial fibrillation , which can be used alone
or in conjunction with digoxin (beta-adrenergic blocking
agents and verapamil), may make the use of high dose s of
digoxin superfluous.
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